ArticleApplied microbiology and biotechnology2025
Bacillus spore showcasing key antigens of African swine fever potentializes a promising oral vaccine candidate.
Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Construction of an Oral Vaccine Based on Multiple Antigens of African Swine Fever Virus Displayed on the Surface of Bacillus Subtilis Spores and Study of its Immune Effect in Rats.Current microbiology · 2026Article
- A three-plasmid-containing CRISPR-Cas9 platform to engineerApplied and environmental microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
African swine fever (ASF) remains a widespread and fatal infectious disease affecting both domestic pigs and wild boars around the world, and there is still no vaccine available for full protection. In recent years, Bacillus spores have been developed into effective vaccine carriers. Here, Bacillus amyloliquefaciens spores from strain CPLK1314 were used as a vaccine delivery system to display three highly antigenic proteins, p72, p30, and p54 of ASF, and their immune responses in BALB/c mice were evaluated. Our results demonstrated that the antibiotic-free Bacillus gene editing system constructed in this study can work effectively, and p72 and the fusion antigen p3054 were successfully expressed in the spore coat of CPLK1314 by fusing with CotB and CotG, respectively. Further animal experiments showed that the recombinant spores ΔBa72 and ΔBa3054 exhibited good immunogenicity, which induced high levels of antigen-specific serum IgG, proliferation of splenic lymphocytes, secretion of immune-related factors, as well as a significant increase in the proportion of T lymphocytes CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.